Nizubaglustat (AZ-3102) is an experimental oral drug currently being studied as a possible treatment for certain rare inherited diseases affecting the nervous system — including GM2 gangliosidosis, that is, Tay-Sachs and Sandhoff disease.
It is a small molecule developed by Azafaros, designed so that after administration it reaches the brain and the central nervous system — which is essential in treating GM2 gangliosidosis. The drug acts on the metabolism of fatty substances and reduces their accumulation in cells, which may slow damage to the nervous system.
The drug has a dual mechanism of action — it acts on two important enzymes involved in glycolipid metabolism. It is being studied in three conditions: Niemann-Pick disease type C, GM1 gangliosidosis and GM2 gangliosidosis.
A global phase III clinical trial called NAVIGATE (NCT07054515) is currently under way — a randomised, double-blind, placebo-controlled study following safety and efficacy in patients aged 4 and over with the late infantile and juvenile forms of these diseases.
Results of the phase II RAINBOW study from 2026 showed that the drug was safe and well tolerated, with encouraging signs of effect — in some patients with GM2 gangliosidosis and NPC, disease progression slowed and the number of seizures fell.
Nizubaglustat has received Orphan Drug Designation and Rare Pediatric Disease Designation in the USA. These designations do not, however, mean approval or wide availability for patients — the drug remains experimental and its real benefit is being verified in ongoing clinical trials.